As patients with rheumatic musculoskeletal disease age, the number of medications they take may increase (i.e., polypharmacy), which can result in unwanted side effects and serious adverse effects. Lee et al. offer considerations and insights into caring for aging patients in a polypharmacy situation to better meet their health and lifestyle needs.
Search results for: treat-to-target
A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA
Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? In a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal. Clinical practice guidelines from…
Treat to Target Lowers the Risk of Fracture in Patients with Gout
Using data from the U.K.’s Health Improvement Network, a primary care database, Wei et al. examined whether urate-lowering therapy (ULT) in a treat-to-target approach for patients with gout reduces the risk of fracture.
Measuring Up: A Review of the ACR-Owned Quality Measures
Since 2006, the Centers for Medicaid & Medicare Services (CMS) has increasingly driven clinicians to focus on and improve quality. Quality measures help clinicians measure how well they treat their patients. By tracking their performance, clinicians can identify opportunities to improve patient care while meeting federal reporting requirements. Breaking Down Quality Measures The CMS has…
Tigulixostat Promising for Patients with Gout & Hyperuricemia
In a dose-finding, clinical trial, Terkeltaub et al. examined the safety and efficacy of tigulixostat, a nonpurine xanthine oxidase inhibitor, for lowering the serum urate levels of patients with gout and hyperuricemia.
Many Medications: Understanding the Biologic Management of Psoriasis
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
Point-of-Care Uric Acid Testing
In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…
ACR Convergence 2022 Closing Session Discusses Research Highlights
PHILADELPHIA—Expert panelists gathered in the closing session at ACR Convergence 2022 to give their take on what they saw as some of the most notable research findings and other insights to come out of the meeting, touching on a number of topics on the leading edge of the field. COVID-19 Prophylaxis & Vaccinations Alfred Kim,…
3 AC&R Study Summaries: Treat to Target in Gout, Response to Biologics in Patients with JIA, & Rehabilitation Dose in Adults with RA
Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use…
Overcoming Healthcare Disparity
PHILADELPHIA—Quality improvement (QI) tools in pediatric rheumatology can help overcome health outcome disparities that are based on race, gender identity, income and other factors, experts said in a session at ACR Convergence. With it well established that these disparities exist, it’s time to begin eliminating them, said Emily Smitherman, MD, MS, assistant professor of pediatric…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 16
- Next Page »